BioAge Labs Says Drug Candidate Shows 'Best-in-Class Reductions' in Inflammatory Biomarkers in Phase 1 Trial With Obese Patients

MT Newswires Live

Apr 21

BioAge Labs (BIOA) said Tuesday its experimental BGE-102 drug demonstrated "best-in-class reductions" in inflammatory biomarkers during a phase 1 trial involving participants with obesity.

Both the 60 mg and 120 mg daily doses lowered high-sensitivity C-reactive protein levels by at least 85% while maintaining a favorable safety profile, the company said.

The company plans to begin a phase 2 study focused on cardiovascular risk during H1, with initial data expected by the end of the year.

BioAge also intends to launch a separate proof-of-concept trial for diabetic macular edema in mid-2026 to evaluate the treatment's effect on retinal diseases.

Shares of the company rose 9% in Tuesday's premarket activity.

Price: 20.49, Change: +1.69, Percent Change: +8.99

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2629357730"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2629357730\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2629357730?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-21 19:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629357730","market":"us","top_or_hot":-1,"title":"BioAge Labs Says Drug Candidate Shows 'Best-in-Class Reductions' in Inflammatory Biomarkers in Phase 1 Trial With Obese Patients","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/BIOA\">BioAge Labs</a> (BIOA) said Tuesday its experimental BGE-102 drug demonstrated \"best-in-class reductions\" in inflammatory biomarkers during a phase 1 trial involving participants with obesity.</p><p>Both the 60 mg and 120 mg daily doses lowered high-sensitivity C-reactive protein levels by at least 85% while maintaining a favorable safety profile, the company said.</p><p>The company plans to begin a phase 2 study focused on cardiovascular risk during H1, with initial data expected by the end of the year.</p><p>BioAge also intends to launch a separate proof-of-concept trial for diabetic macular edema in mid-2026 to evaluate the treatment's effect on retinal diseases.</p><p>Shares of the company rose 9% in Tuesday's premarket activity.</p><p>Price: 20.49, Change: +1.69, Percent Change: +8.99</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioAge Labs Says Drug Candidate Shows 'Best-in-Class Reductions' in Inflammatory Biomarkers in Phase 1 Trial With Obese Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioAge Labs Says Drug Candidate Shows 'Best-in-Class Reductions' in Inflammatory Biomarkers in Phase 1 Trial With Obese Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-21 19:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/BIOA\">BioAge Labs</a> (BIOA) said Tuesday its experimental BGE-102 drug demonstrated \"best-in-class reductions\" in inflammatory biomarkers during a phase 1 trial involving participants with obesity.</p><p>Both the 60 mg and 120 mg daily doses lowered high-sensitivity C-reactive protein levels by at least 85% while maintaining a favorable safety profile, the company said.</p><p>The company plans to begin a phase 2 study focused on cardiovascular risk during H1, with initial data expected by the end of the year.</p><p>BioAge also intends to launch a separate proof-of-concept trial for diabetic macular edema in mid-2026 to evaluate the treatment's effect on retinal diseases.</p><p>Shares of the company rose 9% in Tuesday's premarket activity.</p><p>Price: 20.49, Change: +1.69, Percent Change: +8.99</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2629357730","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629357730","pubTimestamp":1776771882,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BioAge Labs  said Tuesday its experimental BGE-102 drug demonstrated \"best-in-class reductions\" in inflammatory biomarkers during a phase 1 trial involving participants with obesity.Both the 60 mg and 120 mg daily doses lowered high-sensitivity C-reactive protein levels by at least 85% while maintaining a favorable safety profile, the company said.The company plans to begin a phase 2 study focused on cardiovascular risk during H1, with initial data expected by the end of the year.BioAge also intends to launch a separate proof-of-concept trial for diabetic macular edema in mid-2026 to evaluate the treatment's effect on retinal diseases.Shares of the company rose 9% in Tuesday's premarket activity.Price: 20.49, Change: +1.69, Percent Change: +8.99","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BIOA":"BioAge Labs Inc."},"translate_title":"BioAge Labs表示，候选药物在针对肥胖患者的1期试验中显示出“同类最佳的炎症生物标志物减少”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIOA":1.5},"content_text":"BioAge Labs (BIOA) said Tuesday its experimental BGE-102 drug demonstrated \"best-in-class reductions\" in inflammatory biomarkers during a phase 1 trial involving participants with obesity.Both the 60 mg and 120 mg daily doses lowered high-sensitivity C-reactive protein levels by at least 85% while maintaining a favorable safety profile, the company said.The company plans to begin a phase 2 study focused on cardiovascular risk during H1, with initial data expected by the end of the year.BioAge also intends to launch a separate proof-of-concept trial for diabetic macular edema in mid-2026 to evaluate the treatment's effect on retinal diseases.Shares of the company rose 9% in Tuesday's premarket activity.Price: 20.49, Change: +1.69, Percent Change: +8.99","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}